Harrow Overview
Valuation check: HROW's ROE is -52.12%, below the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow-52.12%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Harrow (HROW) currently reports a ROE of -52.12%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Harrow's ROE history and peer comparisons.
Harrow's ROE of -52.12% is lower than the Healthcare sector average of 29.33%. That is roughly 277.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Harrow's current -52.12% should be judged against Healthcare norms (sector average: 29.33%) and against HROW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -52.12%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Harrow, and consider following HROW for alerts when major investors trade the stock.
Harrow is classified in the Healthcare sector. On ROE, it currently shows -52.12% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HROW with unrelated industries.
